Elevated calcium levels in the blood—a complication of kidney cancers known as hypercalcemia—may be successfully treated with HIF-2α inhibitors developed by UT Southwestern Medical Center.
Researchers at the UC San Diego School of Medicine engineered a new anti-αvβ3 antibody that activates macrophages—a type of immune cell already abundant in advanced αvβ3+ tumors—and were able to trigger anti-tumor responses in both patient tumor samples and in mouse models.
